Radiopharm Theranostics Ltd (RADX) SEC filings

RADXNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as RDPTF

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Sep 30, 2026Score 6/30

$0.76−0.03 (-3.80%)

Close on Nov 13, 2026Market cap $8.98MP/E –Yield –

SEC filings

40 of Radiopharm Theranostics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	6-K	Nov 12, 2026	Nov 12, 2026	SEC EDGAR
Current report	6-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Current report	6-K	Oct 30, 2026	Oct 30, 2026	SEC EDGAR
Current report	6-K	Oct 27, 2026	Oct 27, 2026	SEC EDGAR
Current report	6-K	Oct 26, 2026	Oct 26, 2026	SEC EDGAR
Current report	6-K	Oct 20, 2026	Oct 20, 2026	SEC EDGAR
Current report	6-K	Oct 5, 2026	Oct 5, 2026	SEC EDGAR
Current report	6-K	Oct 1, 2026	Oct 1, 2026	SEC EDGAR
Annual report	20-F	Jun 30, 2026	Sep 30, 2026	SEC EDGAR
Current report	6-K	Sep 30, 2026	Sep 30, 2026	SEC EDGAR
Current report	6-K	Sep 22, 2026	Sep 22, 2026	SEC EDGAR
Current report	6-K	Sep 14, 2026	Sep 14, 2026	SEC EDGAR
Current report	6-K	Sep 11, 2026	Sep 11, 2026	SEC EDGAR
Current report	6-K	Sep 9, 2026	Sep 9, 2026	SEC EDGAR
Current report	6-K	Aug 28, 2026	Aug 28, 2026	SEC EDGAR
Current report	6-K	Aug 27, 2026	Aug 27, 2026	SEC EDGAR
Current report	6-K	Aug 26, 2026	Aug 26, 2026	SEC EDGAR
Current report	6-K	Aug 20, 2026	Aug 20, 2026	SEC EDGAR
Current report	6-K	Aug 17, 2026	Aug 17, 2026	SEC EDGAR
Current report	6-K	Aug 13, 2026	Aug 13, 2026	SEC EDGAR
Current report	6-K	Aug 3, 2026	Aug 3, 2026	SEC EDGAR
Current report	6-K	Jul 31, 2026	Jul 31, 2026	SEC EDGAR
Current report	6-K	Jul 28, 2026	Jul 28, 2026	SEC EDGAR
Current report	6-K	Jul 28, 2026	Jul 28, 2026	SEC EDGAR
Current report	6-K	Jul 27, 2026	Jul 27, 2026	SEC EDGAR
Current report	6-K	Jul 24, 2026	Jul 24, 2026	SEC EDGAR
Current report	6-K	Jul 22, 2026	Jul 22, 2026	SEC EDGAR
Current report	6-K	Jul 3, 2026	Jul 6, 2026	SEC EDGAR
Current report	6-K	Jun 30, 2026	Jun 30, 2026	SEC EDGAR
Current report	6-K	Jun 3, 2026	Jun 3, 2026	SEC EDGAR
Current report	6-K	May 1, 2026	May 1, 2026	SEC EDGAR
Current report	6-K	Apr 23, 2026	Apr 23, 2026	SEC EDGAR
Current report	6-K	Apr 20, 2026	Apr 20, 2026	SEC EDGAR
Current report	6-K	Apr 16, 2026	Apr 16, 2026	SEC EDGAR
Current report	6-K	Apr 8, 2026	Apr 8, 2026	SEC EDGAR
Current report	6-K	Apr 7, 2026	Apr 7, 2026	SEC EDGAR
Current report	6-K	Mar 27, 2026	Mar 27, 2026	SEC EDGAR
Current report	6-K	Mar 24, 2026	Mar 24, 2026	SEC EDGAR
Current report	6-K	Mar 19, 2026	Mar 19, 2026	SEC EDGAR
Current report	6-K	Feb 27, 2026	Feb 27, 2026	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Radiopharm Theranostics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RADX.

Compare: RADX vs PCT · RADX vs TXMD · RADX vs CLLS · RADX vs OLOX · RADX vs PTCHF

Revenue growth-23.8% · median 33.9%

Operating margin-2051.5% · median -353.2%

Company	Revenue	Growth
PCT	$13.68M	+141.7%
OLOX	$4.07M	-0.4%
TXMD	$3.75M	+33.9%
RADX	$2.77M	-23.8%
CLLS	–	–
PTCHF	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: June 30
Employees: 2
Auditor: GRANT THORNTON AUDIT PTY LTD
SEC CIK: 1949257

Advertisement
300 × 250

See a number that looks wrong?